Skip to main content

ORIGINAL RESEARCH article

Front. Pediatr.
Sec. Neonatology
Volume 12 - 2024 | doi: 10.3389/fped.2024.1465785

Vasopressin Induced Hyponatremia in Infants <3 Months of Age in the Neonatal Intensive Care Unit

Provisionally accepted
Kavita Patel Kavita Patel 1Meera Vijayan Meera Vijayan 2Sharon Thomson Sharon Thomson 3Marjorie Makoni Marjorie Makoni 3,4Peter Johnson Peter Johnson 3,5*Katy Stephens Katy Stephens 3Stephen B. Neely Stephen B. Neely 5Jamie Miller Jamie Miller 3,5
  • 1 university health at san antonio, San Antonio, United States
  • 2 Lucile Packard Children's Hospital, Palo Alto, California, United States
  • 3 Oklahoma Children's Hospital, College of Medicine, University of Oklahoma, Oklahoma City, United States
  • 4 College of Medicine, University of Oklahoma, Oklahoma City, Oklahoma, United States
  • 5 College of Pharmacy, University of Oklahoma, Oklahoma City, Oklahoma, United States

The final, formatted version of the article will be published soon.

    Objectives: Vasopressin is used for shock and acute pulmonary hypertension in the neonatal intensive care unit (NICU) and is associated with hyponatremia. The purpose of this study was to determine the incidence, severity, contributing risk factors associated with vasopressin-induced hyponatremia in neonates and infants <3 months of age in the NICU. The primary objective was to determine the incidence of hyponatremia (<130 mEq/L) and severe hyponatremia (< 125 mEq/L). The secondary objectives were to compare clinical characteristics and the vasopressin regimen between those with and without hyponatremia.Methods: This retrospective cohort study included neonates and infants <3 months from 1/1/2017-12/31/2022 receiving vasopressin for >6 hours. Analyses were performed using SAS v9.4, with a priori less than 0.05. A multiple variable logistic regression was employed to assess odds of hyponatremia.Of the 105 patients included, 57 (54.3%) developed hyponatremia, and 17 (29.8%) were classified as severe hyponatremia. Overall, the median (interquartile range, IQR) gestational and postnatal age at vasopressin initiation were 35.4 (27-38.7) weeks and 2 (1-12) days. There was no difference in vasopressin dose, but duration of treatment was longer in those with hyponatremia. Higher baseline serum sodium was associated with decreased odds of hyponatremia [adjusted odds ratio (OR): 0.90 (95% CI: 0.83-0.99), p=0.03], and increased vasopressin duration was associated with increased odds of hyponatremia [aOR: 1.02 (95% CI:1.01-1.03), p<0.001].Conclusions: Hyponatremia occurred in half of patients included. The pre-vasopressin sodium value and the vasopressin duration were independently associated with hyponatremia.

    Keywords: Hyponatremia, infants, neonatal intensive care unit, neonates, vasopressin

    Received: 16 Jul 2024; Accepted: 09 Sep 2024.

    Copyright: © 2024 Patel, Vijayan, Thomson, Makoni, Johnson, Stephens, Neely and Miller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Peter Johnson, College of Pharmacy, University of Oklahoma, Oklahoma City, 73117, Oklahoma, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.